Previous close | 0.9301 |
Open | 0.9456 |
Bid | 0.6620 x 200 |
Ask | 0.9419 x 100 |
Day's range | 0.9000 - 0.9456 |
52-week range | 0.8900 - 3.3700 |
Volume | |
Avg. volume | 140,311 |
Market cap | 4.952M |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8800 |
Earnings date | 09 Aug 2024 - 13 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.67 |
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the EF Hutton Annual Global Conference in New York, NY.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant